| scholarly article | Q13442814 |
| P2093 | author name string | M Denton | |
| P Smith | |||
| K Rogers | |||
| A Perry | |||
| E Hart | |||
| A D Streblow | |||
| C N Kreklywich | |||
| C Pallett | |||
| D N Streblow | |||
| I Messaoudi | |||
| M Chuop | |||
| M Slifka | |||
| R Broekel | |||
| S L Orloff | |||
| T Andoh | |||
| Y K Hwee | |||
| P2860 | cites work | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. | Q54038587 |
| Evaluation of Cytomegalovirus (CMV)–Specific T Cell Immune Reconstitution Revealed That Baseline Antiviral Immunity, Prophylaxis, or Preemptive Therapy but not Antithymocyte Globulin Treatment Contribute to CMV‐Specific T Cell Reconstitution in K | Q60213345 | ||
| Biology of rat cytomegalovirus infection | Q70101215 | ||
| Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine | Q70217371 | ||
| Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection | Q71807738 | ||
| Rat cytomegalovirus: induction of and sensitivity to interferon | Q72727033 | ||
| A rat small bowel transplant model of chronic rejection: histopathologic characteristics | Q73068828 | ||
| Morphometric analysis of neointimal formation in murine cardiac allografts | Q73251439 | ||
| Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC | Q73677700 | ||
| Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection | Q73752172 | ||
| The antiinflammatory activity of IgG: the intravenous IgG paradox | Q24676548 | ||
| Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols | Q27477631 | ||
| Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants | Q31043979 | ||
| Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant | Q33585524 | ||
| Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus | Q33903818 | ||
| Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts | Q34169756 | ||
| Cytomegalovirus microRNA expression is tissue specific and is associated with persistence | Q34457773 | ||
| Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants | Q34467148 | ||
| Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial | Q34786700 | ||
| Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. | Q34988279 | ||
| Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients | Q35032659 | ||
| Cytomegalovirus and lung transplantation | Q35842707 | ||
| Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins | Q35946943 | ||
| Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection | Q36023008 | ||
| Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients | Q36266751 | ||
| Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. | Q36363051 | ||
| Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects | Q36402863 | ||
| Development of a new hydrogen peroxide–based vaccine platform. | Q36423118 | ||
| Desirability and feasibility of a vaccine against cytomegalovirus | Q38100041 | ||
| Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients | Q40360861 | ||
| Cytomegalovirus and latency: an overview. | Q40735638 | ||
| The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. | Q41946457 | ||
| Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines | Q42230760 | ||
| High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy | Q43833983 | ||
| Ganciclovir-resistant cytomegalovirus in organ transplant recipients | Q44000196 | ||
| Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. | Q45084505 | ||
| The development of vaccines: how the past led to the future | Q45197725 | ||
| Cellular immune responses to cytomegalovirus in renal transplant recipients | Q45214565 | ||
| Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. | Q45781852 | ||
| Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. | Q45881220 | ||
| Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge | Q46111260 | ||
| Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. | Q46786257 | ||
| A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. | Q50976609 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P304 | page(s) | 1805-1816 | |
| P577 | publication date | 2015-03-12 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts | |
| P478 | volume | 15 |
| Q91675842 | A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection |
| Q40380028 | Disruption of Transplant Tolerance by an "Incognito" Form of CD8 T Cell-Dependent Memory |
| Q58801058 | Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection |
| Q60960757 | Pathogen at the Gates: Human Cytomegalovirus Entry and Cell Tropism |
Search more.